Long-term gene therapy with thrombospondin 2 inhibits TGF-β activation, inflammation and angiogenesis in chronic allograft nephropathy

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Daniel, Christoph ^a   Vogelbacher, Regina ^a   Stief, Andrea ^a   Grigo, Christina ^a   Hugo, Christian ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOSPONDIN; THROMBOSPONDIN 2; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN;

ALLOGRAFT; ANIMAL; CELL LINE; GENE THERAPY; GENETICS; INFLAMMATION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PROCEDURES; PROMOTER REGION; RAT; TIME;

ALLOGRAFTS; ANIMALS; CELL LINE; GENETIC THERAPY; INFLAMMATION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; RATS; THROMBOSPONDINS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN;

EID: 84893507851     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083846     Document Type: Article

References (58)

1. Lamb KE, Lodhi S, Meier-Kriesche HU (2010) Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 11: 450-462.
2. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B (2004) Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4: 378-383. (Pubitemid 38282293)
3. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB (2002) Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 346: 580-590. (Pubitemid 34438820)
4. El-Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, et al. (2009) Identifying specific causes of kidney allograft loss. Am J Transplant 9: 527-535.
5. Campistol JM, Inigo P, Larios S, Bescos M, Oppenheimer F (2001) Role of transforming growth factor-beta1 in the progression of chronic allograft nephropathy. Nephrol Dial Transplant 16 Suppl 1: 114-116. (Pubitemid 32492521)
6. Djamali A, Samaniego M (2009) Fibrogenesis in kidney transplantation: potential targets for prevention and therapy. Transplantation 88: 1149-1156.
7. Harris S, Coupes BM, Roberts SA, Roberts IS, Short CD, et al. (2007) TGF-beta1 in chronic allograft nephropathy following renal transplantation. J Nephrol 20: 177-185. (Pubitemid 47072401)
8. Einecke G, Reeve J, Sis B, Mengel M, Hidalgo L, et al. (2010) A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J Clin Invest 120: 1862-1872.
9. Yin ZK, Wu XH, Xia YG, Luo CL (2011) Transforming growth factor-beta1 short hairpin RNA inhibits renal allograft fibrosis. Chin Med J (Engl) 124: 655-663.
10. Lawrence DA (1996) Transforming growth factor-beta: a general review. Eur Cytokine Netw 7: 363-374.
11. Hugo C, Daniel C (2009) Thrombospondin in renal disease. Nephron Exp Nephrol 111: e61-66.
12. Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE (1999) The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem 274: 13586-13593.
13. Young GD, Murphy-Ullrich JE (2004) The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex. J Biol Chem 279: 47633-47642. (Pubitemid 39540909)
14. Schultz-Cherry S, Chen H, Mosher DF, Misenheimer TM, Krutzsch HC, et al. (1995) Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J Biol Chem 270: 7304-7310.
15. Daniel C, Wagner A, Hohenstein B, Hugo C (2009) Thrombospondin-2 therapy ameliorates experimental glomerulonephritis via inhibition of cell proliferation, inflammation, and TGF-beta activation. Am J Physiol Renal Physiol 297: F1299-1309.
16. Papageorgiou AP, Swinnen M, Vanhoutte D, Vandendriessche T, Chuah M, et al. (2012) Thrombospondin-2 prevents cardiac injury and dysfunction in viral myocarditis through the activation of regulatory T-cells. Cardiovasc Res 94: 115-124.
17. Swinnen M, Vanhoutte D, Van Almen GC, Hamdani N, Schellings MW, et al. (2009) Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation 120: 1585-1597.
18. Gill DR, Smyth SE, Goddard CA, Pringle IA, Higgins CF, et al. (2001) Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter. Gene Ther 8: 1539-1546. (Pubitemid 33061892)
19. Johnson RJ, Pritzl P, Iida H, Alpers CE (1991) Platelet-complement interactions in mesangial proliferative nephritis in the rat. Am J Pathol 138: 313-321.
20. Vogelbacher R, Meister S, Guckel E, Starke C, Wittmann S, et al. (2010) Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat. Nephrol Dial Transplant 25: 3764-3773.
21. Iruela-Arispe L, Gordon K, Hugo C, Duijvestijn AM, Claffey KP, et al. (1995) Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 147: 1715-1727.
22. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, et al. (2001) Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 12: 1434-1447. (Pubitemid 32666326)
23. Daniel C, Takabatake Y, Mizui M, Isaka Y, Kawashi H, et al. (2003) Antisense oligonucleotides against thrombospondin-1 inhibit activation of tgf-beta in fibrotic renal disease in the rat in vivo. Am J Pathol 163: 1185-1192. (Pubitemid 37040154)
24. Keller K, Daniel C, Schocklmann H, Endlich KH, Kerjaschki D, et al. (2006) Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. Nephrol Dial Transplant 21: 2724-2735. (Pubitemid 44542224)
25. Daniel C, Wiede J, Krutzsch HC, Ribeiro SM, Roberts DD, et al. (2004) Thrombospondin-1 is a major activator of TGF-beta in fibrotic renal disease in the rat in vivo. Kidney Int 65: 459-468. (Pubitemid 38130640)
26. Hugo C, Pichler R, Meek R, Gordon K, Kyriakides T, et al. (1995) Thrombospondin 1 is expressed by proliferating mesangial cells and is up-regulated by PDGF and bFGF in vivo. Kidney Int 48: 1846-1856.
27. Dimmler A, Haas CS, Cho S, Hattler M, Forster C, et al. (2003) Laser capture microdissection and real-time PCR for analysis of glomerular endothelin-1 gene expression in mesangiolysis of rat anti-Thy 1.1 and murine Habu Snake Venom glomerulonephritis. Diagn Mol Pathol 12: 108-117. (Pubitemid 36627193)
28. Laulajainen T, Julkunen I, Haltia A, Knuutila S, Miettinen A, et al. (1993) Establishment and characterization of a rat glomerular endothelial cell line. Lab Invest 69: 183-192. (Pubitemid 23262498)
29. Wittmann S, Daniel C, Braun A, Vogelbacher R, Shimizu F, et al. (2008) The mTOR inhibitor everolimus attenuates the time course of chronic anti-Thy1 nephritis in the rat. Nephron Exp Nephrol 108: e45-56. (Pubitemid 351346991)
30. Jevnikar AM, Mannon RB (2008) Late kidney allograft loss: what we know about it, and what we can do about it. Clin J Am Soc Nephrol 3 Suppl 2: S56-67.
31. Daniel C, Schaub K, Amann K, Lawler J, Hugo C (2007) Thrombospondin-1 is an endogenous activator of TGF-beta in experimental diabetic nephropathy in vivo. Diabetes 56: 2982-2989. (Pubitemid 350223633)
32. Hugo C, Kang DH, Johnson RJ (2002) Sustained expression of thrombospondin-1 is associated with the development of glomerular and tubulointerstitial fibrosis in the remnant kidney model. Nephron 90: 460-470. (Pubitemid 34310111)
33. Abrass CK (2000) The nature of chronic progressive nephropathy in aging rats. Adv Ren Replace Ther 7: 4-10.
34. Hugo C, Shankland SJ, Pichler RH, Couser WG, Johnson RJ (1998) Thrombospondin 1 precedes and predicts the development of tubulointerstitial fibrosis in glomerular disease in the rat. Kidney Int 53: 302-311. (Pubitemid 28097847)
35. Hotchkiss H, Chu TT, Hancock WW, Schroppel B, Kretzler M, et al. (2006) Differential expression of profibrotic and growth factors in chronic allograft nephropathy. Transplantation 81: 342-349. (Pubitemid 43255717)
36. McGregor B, Colon S, Mutin M, Chignier E, Zech P, et al. (1994) Thrombospondin in human glomerulopathies. A marker of inflammation and early fibrosis. Am J Pathol 144: 1281-1287. (Pubitemid 24172090)
37. Altun B, Usalan C, Haznedaroglu IC, Arici M, Ulusoy S, et al. (1999) Thrombopoietin and thrombospondin in renal allograft recipients. Blood Coagul Fibrinolysis 10: 233-237. (Pubitemid 29382662)
38. Daniel C, Amann K, Hohenstein B, Bornstein P, Hugo C (2007) Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in experimental glomerulonephritis in mice. J Am Soc Nephrol 18: 788-798. (Pubitemid 46434496)
39. Park YW, Kang YM, Butterfield J, Detmar M, Goronzy JJ, et al. (2004) Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Am J Pathol 165: 2087-2098. (Pubitemid 39578386)
40. Lamy L, Foussat A, Brown EJ, Bornstein P, Ticchioni M, et al. (2007) Interactions between CD47 and thrombospondin reduce inflammation. J Immunol 178: 5930-5939. (Pubitemid 46674390)
41. Sarkozi R, Flucher K, Haller VM, Pirklbauer M, Mayer G, et al. (2012) Oncostatin M inhibits TGF-beta1-induced CTGF expression via STAT3 in human proximal tubular cells. Biochem Biophys Res Commun 424: 801-806.
42. Wang Q, Usinger W, Nichols B, Gray J, Xu L, et al. (2011) Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease. Fibrogenesis Tissue Repair 4: 4.
43. Liu Y, Meyer C, Muller A, Herweck F, Li Q, et al. (2011) IL-13 induces connective tissue growth factor in rat hepatic stellate cells via TGF-beta-independent Smad signaling. J Immunol 187: 2814-2823.
44. Rodder S, Scherer A, Raulf F, Berthier CC, Hertig A, et al. (2009) Renal allografts with IF/TA display distinct expression profiles of metzincins and related genes. Am J Transplant 9: 517-526.
45. Kajihara I, Jinnin M, Yamane K, Makino T, Honda N, et al. (2012) Increased accumulation of extracellular thrombospondin-2 due to low degradation activity stimulates type I collagen expression in scleroderma fibroblasts. Am J Pathol 180: 703-714.
46. Reinecke H, Robey TE, Mignone JL, Muskheli V, Bornstein P, et al. (2012) Lack of thrombospondin-2 reduces fibrosis and increases vascularity around cardiac cell grafts. Cardiovasc Pathol 22: 91-95.
47. Campanholle G, Ligresti G, Gharib SA, Duffield JS (2013) Cellular Mechanisms of Tissue Fibrosis. 3. Novel mechanisms of kidney fibrosis. Am J Physiol Cell Physiol 304: C591-603.
48. Steegh FM, Gelens MA, Nieman FH, van Hooff JP, Cleutjens JP, et al. (2011) Early loss of peritubular capillaries after kidney transplantation. J Am Soc Nephrol 22: 1024-1029.
49. Kyriakides TR, Leach KJ, Hoffman AS, Ratner BD, Bornstein P (1999) Mice that lack the angiogenesis inhibitor, thrombospondin 2, mount an altered foreign body reaction characterized by increased vascularity. Proc Natl Acad Sci U S A 96: 4449-4454. (Pubitemid 29190356)
50. Kyriakides TR, Tam JW, Bornstein P (1999) Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J Invest Dermatol 113: 782-787.
51. Kyriakides TR, Zhu YH, Yang Z, Huynh G, Bornstein P (2001) Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am J Pathol 159: 1255-1262. (Pubitemid 32947955)
52. Tomii Y, Kamochi J, Yamazaki H, Sawa N, Tokunaga T, et al. (2002) Human thrombospondin 2 inhibits proliferation of microvascular endothelial cells. Int J Oncol 20: 339-342.
53. Mirochnik Y, Kwiatek A, Volpert OV (2008) Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. Curr Drug Targets 9: 851-862.
54. Armstrong LC, Bjorkblom B, Hankenson KD, Siadak AW, Stiles CE, et al. (2002) Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell 13: 1893-1905. (Pubitemid 34651480)
55. Oganesian A, Armstrong LC, Migliorini MM, Strickland DK, Bornstein P (2008) Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. Mol Biol Cell 19: 563-571. (Pubitemid 351272145)
56. Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J, et al. (2007) Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 210: 807-818. (Pubitemid 46185050)
57. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, et al. (2003) Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 63: 5224-5229. (Pubitemid 37139832)
58. Kroening S, Neubauer E, Wullich B, Aten J, Goppelt-Struebe M (2010) Characterization of connective tissue growth factor expression in primary cultures of human tubular epithelial cells: modulation by hypoxia. Am J Physiol Renal Physiol 298: F796-806.